- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07693790
Augmented Reality Training for Amblyopia After Congenital Cataract Surgery
Effectiveness and Safety of Augmented Reality-Based Amblyopia Training for Postoperative Congenital Cataract Patients: A Multicenter, Superiority, Randomized, Parallel-Controlled Trial Protocol
This study will evaluate whether augmented reality training is effective and safe for treating unilateral amblyopia after congenital cataract surgery in children.
Children aged 5 to 12 years with unilateral amblyopia after congenital cataract surgery will be enrolled from three eye hospitals in China. Participants will be randomly assigned to one of two groups. One group will receive augmented reality amblyopia training for 2 hours per day for 4 months. The other group will receive conventional patching of the fellow eye for 4 hours per day for 4 months.
The main outcome is the change in best-corrected visual acuity of the amblyopic eye after 4 months of treatment. The study will also evaluate contrast sensitivity, binocular visual function, stereoacuity, vision-related symptoms, quality of life, and adverse events.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a multicenter, randomized, parallel-group, superiority clinical trial designed to evaluate the efficacy and safety of augmented reality training for children with unilateral amblyopia after congenital cataract surgery.
The study plans to enroll 88 participants aged 5 to 12 years who have unilateral amblyopia after congenital cataract surgery. Eligible participants will be randomly assigned in a 1:1 ratio to either the experimental group or the control group. The experimental group will receive augmented reality amblyopia training for 2 hours per day for 4 months. The control group will receive conventional patching of the fellow eye for 4 hours per day for 4 months.
The study includes a screening period, a baseline visit, and follow-up visits after 1 month and 4 months of treatment. The primary outcome is the change from baseline in best-corrected visual acuity of the amblyopic eye, measured in logMAR units, at 4 months. Secondary outcomes include contrast sensitivity, suppression status, stereoacuity, and quality of life assessed using the Chinese version of the PedsQL 4.0 Generic Core Scales. Safety outcomes include computer vision symptoms assessed using the CVSS-6 scale and the incidence of adverse events, including dizziness, headache, eye fatigue, blurred vision, and skin allergy.
The purpose of this trial is to determine whether augmented reality amblyopia training provides superior improvement in visual acuity compared with conventional patching, while also assessing its effects on binocular visual function and treatment safety in this patient population.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Ruixin Wang
- Telefonnummer: +86-20-87332702
- E-mail: wangruixin@gzzoc.com
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Aged 5 to 12 years, male or female.
- Diagnosed with unilateral amblyopia after congenital cataract surgery.
- Best-corrected visual acuity (BCVA) of the amblyopic eye ≤0.80 logMAR, BCVA of the fellow eye better than 0.15 logMAR, and interocular BCVA difference ≥0.20 logMAR.
- Underwent cataract extraction at age ≤5 years and has stable ocular status at least 2 months after intraocular lens implantation.
- If refractive error is present, optical correction has been worn for at least 3 months.
- Orthophoria, or if strabismus is present, manifest deviation at distance of 6 m is ≤4 prism diopters after strabismus correction as measured by prism cover test.
- Able to understand the study procedures, and written informed consent is obtained from the participant and/or legal guardian as required.
Exclusion Criteria:
- Childhood cataract caused by causes other than congenital cataract, including traumatic, drug-induced, steroid-related, secondary, or metabolic cataract.
- Other ocular organic diseases that may affect visual acuity assessment or amblyopia treatment evaluation, including but not limited to significant ptosis, corneal or other media opacity, glaucoma or persistent ocular hypertension, optic nerve disease, retinal disease, or cortical visual impairment.
- Uncontrolled or clinically unstable severe systemic disease that may affect study safety, adherence, or outcome assessment, including active malignancy, severe cardiovascular disease, uncontrolled hypertension, epilepsy, or history of photosensitive epilepsy.
- Implanted electronic medical devices that may be affected by the study device or may affect safe use of the device, such as a pacemaker or implantable cardioverter-defibrillator.
- Significant ocular inflammation, photophobia, tearing, eye pain, or other ocular surface or anterior segment disease at screening that may affect visual acuity testing, device wearing, or completion of training.
- Obvious dizziness, motion sickness, acrophobia, balance disorder, or sequelae of previous brain injury that may affect safe wearing of the augmented reality device or training adherence.
- Facial trauma, craniofacial deformity, or head and facial structural abnormality that may affect normal wearing, positioning, or safe use of the augmented reality device.
- Severe psychiatric, cognitive, developmental, or behavioral disorder that may prevent understanding of study procedures, completion of training, or follow-up.
- Current or planned use of medications that may affect visual acuity, refractive status, pupil status, or visual function assessment, except for short-term cycloplegic agents used for routine ophthalmic examination.
- Unable to simultaneously perceive binocular stimuli in the device or unable to complete binocular simultaneous vision training after device screening or calibration.
- Received amblyopia treatment other than spectacle correction within 2 weeks before screening, including patching, atropine penalization, visual training, binocular vision training, or other amblyopia-related interventions.
- Participation in another drug clinical trial within 3 months or another medical device clinical trial within 1 month before screening.
- Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Augmented Reality Amblyopia Training
Participants in this arm will receive augmented reality amblyopia training for 2 hours per day for 4 months.
Training may be completed in divided sessions, with each session lasting at least 30 minutes when possible.
The training system will record training duration, task completion, and adherence data.
|
Participants assigned to the experimental group will receive augmented reality amblyopia training for 2 hours per day for 4 months.
Training may be completed in divided sessions, with each session lasting at least 30 minutes when possible.
The training system will present visual training tasks and record training duration, task completion, and adherence data.
|
|
Aktiv komparator: Conventional Patching
Participants in this arm will receive conventional patching of the fellow eye for 4 hours per day for 4 months.
Participants or their guardians will record daily patching duration and completion in a treatment diary, and adherence will be reviewed during follow-up visits.
|
Participants assigned to the control group will receive conventional patching of the fellow eye for 4 hours per day for 4 months.
Participants or their guardians will record daily patching duration and completion in a treatment diary, and adherence will be reviewed during follow-up visits.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Best-Corrected Visual Acuity of the Amblyopic Eye at 4 Months
Tidsramme: Baseline, 4 months
|
Best-corrected visual acuity of the amblyopic eye will be measured using the ETDRS visual acuity chart and recorded in logMAR units.
The primary outcome is defined as the change from baseline to 4 months, calculated as baseline logMAR BCVA minus 4-month logMAR BCVA.
A larger positive value indicates greater visual acuity improvement.
|
Baseline, 4 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Contrast Sensitivity at 1 Month and 4 Months
Tidsramme: Baseline, 4 months
|
Contrast sensitivity will be measured using the CSV-1000 test at different spatial frequencies, including 3, 6, 12, and 18 cycles per degree.
Changes from baseline to 1 month and 4 months will be evaluated.
|
Baseline, 4 months
|
|
Change From Baseline in Suppression Status at 1 Month and 4 Months
Tidsramme: Baseline, 4 months
|
Suppression status will be assessed using the Bagolini striated glasses test and the Worth 4-dot test.
The presence or absence of suppression and abnormal retinal correspondence will be recorded and compared across study visits.
|
Baseline, 4 months
|
|
Change From Baseline in Stereoacuity at 1 Month and 4 Months
Tidsramme: Baseline, 4 months
|
Stereoacuity will be assessed using the Randot stereotest for distance and near stereoacuity and the Titmus stereotest for near stereoacuity.
Improvement will be defined as an improvement of at least one stereoacuity level from baseline or a change from no measurable stereoacuity to measurable stereoacuity.
|
Baseline, 4 months
|
|
Change From Baseline in Quality of Life at 1 Month and 4 Months
Tidsramme: Baseline, 4 months
|
Quality of life will be assessed using the Chinese version of the Pediatric Quality of Life Inventory 4.0 Generic Core Scales.
The scale includes physical, emotional, social, and school functioning domains.
Changes from baseline to 1 month and 4 months will be evaluated.
|
Baseline, 4 months
|
|
Change From Baseline in Computer Vision Symptoms at 1 Month and 4 Months
Tidsramme: Baseline, 4 months
|
Computer vision symptoms will be assessed using the CVSS-6 scale.
The scale evaluates symptoms including eye fatigue, blurred vision, dry eye sensation, burning or stinging sensation, increased tearing or discharge, and headache.
The total score ranges from 0 to 18, with higher scores indicating more severe symptoms.
|
Baseline, 4 months
|
|
Incidence of Adverse Events During the Study
Tidsramme: 4 months
|
Adverse events will be recorded throughout the study, including dizziness, headache, eye fatigue, blurred vision, skin allergy, and other discomforts.
The incidence, severity, management, outcome, and relationship to the study intervention will be documented.
|
4 months
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- SQIIT-2026-035
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Medfødt grå stær
-
Opus Genetics, IncIkke rekrutterer endnuLeber medfødt amaurose | Leber Congenital Amaurosis (LCA)Forenede Stater
-
Instituto de Genética OcularAktiv, ikke rekrutterende
-
Cure CMDCongenital Muscle Disease International RegistrTrukket tilbageLAMA2-MD (Merosin Deficient Congenital Muskeldystrofi, MDC1A)Forenede Stater
-
QLT Inc.AfsluttetLCA (Leber Congenital Amaurosis) | RP (Retinitis Pigmentosa)Forenede Stater, Canada, Tyskland, Holland, Det Forenede Kongerige
-
Università Vita-Salute San RaffaeleRekrutteringLAMA2-MD (Merosin Deficient Congenital Muskeldystrofi, MDC1A) | Merosin mangelfuld medfødt muskeldystrofi | Merosin mangelfuld CMD (helt eller delvist) | LAMA2-MD \(Merosin mangelfuld medfødt muskeldystrofi, MDC1A\)Italien
-
MeiraGTx UK II LtdSyne Qua Non LimitedAfsluttetØjensygdomme | Nethindesygdomme | Øjensygdomme, arvelig | Leber Congenital Amaurosis (LCA)Forenede Stater, Det Forenede Kongerige
-
QLT Inc.AfsluttetLeber Congenital Amaurosis (LCA) | Retinitis Pigmentosa (RP)Forenede Stater, Canada, Danmark, Tyskland, Holland, Schweiz, Det Forenede Kongerige
-
QLT Inc.AfsluttetLCA (Leber Congenital Amaurosis) | RP (Retinitis Pigmentosa)Canada, Forenede Stater, Tyskland, Holland, Det Forenede Kongerige
-
Hospital Universitari Vall d'Hebron Research InstituteASOCIACIÓN IMPÚLSATE PARA LA CURA DE LOS NIÑOS CON DÉFICIT DE MEROSINARekrutteringMuskeldystrofier | Kohortestudier | LAMA2-MD (Merosin Deficient Congenital Muskeldystrofi, MDC1A) | Merosin mangelfuld medfødt muskeldystrofi | Merosin mangelfuld CMD (helt eller delvist)Spanien
-
National Human Genome Research Institute (NHGRI)RekrutteringMetabolisk sygdom | Purin-pyrimidin metabolisme | AICDA, OMIM *605257, Immundefekt med Hyper-IgM, Type 2; HIGM2 | UNG, OMIM *191525, Hyper-IgM Syndrome 5 | NT5C3A, OMIM *606224, Anæmi, hæmolytisk, på grund af UMPH1-mangel | UMPS, OMIM *613891, Orotic Aciduria | DHODH, OMIM *126064, Millers syndrom... og andre forholdForenede Stater
Kliniske forsøg med Augmented Reality Amblyopia Training
-
Universiti Teknologi MaraIkke rekrutterer endnuErhvervssygdomme | Arbejdsrelateret lidelse i øvre ekstremiteter
-
H. Lee Moffitt Cancer Center and Research InstituteNational Institute on Drug Abuse (NIDA); National Institutes of Health...Afsluttet
-
University Hospital, Strasbourg, FranceIkke rekrutterer endnu
-
Wayne State UniversityAktiv, ikke rekrutterendeSpecifik fobi, dyrForenede Stater
-
Vanderbilt University Medical CenterVanderbilt University; National Institute for Biomedical Imaging and Bioengineering...Afsluttet
-
Chinese University of Hong KongAfsluttet
-
Vanderbilt University Medical CenterVanderbilt University; National Institute for Biomedical Imaging and Bioengineering...Rekruttering
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUniversity of BolognaRekruttering
-
Brigham and Women's HospitalTrukket tilbageSmerte | Infektion | MalignitetForenede Stater
-
Stanford UniversityAfsluttetAkut smerte | Mobilitetsbegrænsning | Spinal FusionForenede Stater